Estimating Indirect Costs in Primary Sjogren's Syndrome
Estimating Indirect Costs in Primary Sjogren's Syndrome
复制标题
DOI：
10.3899/jrheum.090734
复制
发表时间：
2010-05-01
影响因子：
3.9
通讯作者：
Clarke, Ann E.
中科院分区：
文献类型：
--
作者：
Bowman, Simon J.;Pierre, Yvan St.;Clarke, Ann E.
目标。与类风湿性关节炎(RA)和社区对照相比，估算与原发性干燥综合征(PSS)相关的间接成本。数据来自84名PSS女性患者，作为开发系统活动测量研究的一部分，从87名在医院诊所就诊的连续女性RA患者和96名全科医生名单上的女性社区对照组获得。使用修改后的斯坦福健康评估问卷中的经济部分来评估生产力损失。使用保守模型，估计的年间接成本(95%CI)：PSS组为7677磅(5560磅，9794磅)，RA组为10,444磅(8206磅，12,681磅)，对照组为892磅(307磅，1478磅)。使用最大化估计的模型，相应的数字分别为13,502英镑(9542英镑，17,463)英镑，17,070英镑(13,112英镑，21,028)英镑和3382英镑(2187英镑，4578英镑)。在P<；0.001，患者组的这些指标均显著高于对照组。PSS与显著增加的间接成本相关，相当于RA患者的69%-83%。在评估PSS的总体经济后果时，需要考虑到这一点。(2010年4月1日首次发布；J Rheumatol 2010；37：1010-15；DOI：10.3899/jheurn.090734)
Objective. To estimate the indirect costs associated with primary Sjogren's syndrome (pSS) compared with rheumatoid arthritis (RA) and community controls.Methods. Data were obtained from 84 women patients with pSS as part of a study to develop a systemic activity measure, from 87 consecutive women patients with RA attending a hospital clinic, and from 96 women community controls on a general practice list. A modified economic component of the Stanford Health Assessment Questionnaire was used to assess lost productivity.Results. Using a conservative model, the estimated total annual indirect costs (95% CI) were 7677 pound (5560 pound, 9794) pound for pSS, 10,444 pound (8206 pound, 12,681) pound for RA, and 892 pound (307 pound, 1478) pound for controls. Using a model that maximizes the estimates, the equivalent figures were 13,502 pound (9542 pound, 17,463) pound, 17,070 pound (13,112 pound, 21,028) pound, and 3382 pound (2187 pound, 4578) pound, respectively. These were all significantly greater at p < 0.001 for patient groups than for the control group.Conclusion. pSS is associated with significantly increased indirect costs equivalent to 69%-83% of that for patients with RA. This needs to be taken into account when evaluating the overall economic consequences of pSS. (First Release April 1 2010; J Rheumatol 2010;37:1010-15; doi:10.3899/jrheurn.090734)